Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department"
Moscow, 115446, Russia
Location status: Recruiting
NCT Number: NCT07764172
The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is:
Is the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality?
Participants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.
Interested in participating?
Request Info50 year and older
All sexes
Observational
Moscow, 115446, Russia
Location status: Recruiting
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Discontinuation criteria (drop-out)
Time frame: Baseline and 14 days
Lower scores indicate increasing disability and a greater need for skilled care. Min - 0 ( < 20 - totally dependent), max - 100 ( > 80 - independent).
Time frame: Baseline and 90 days
Min - 0 (no disability), max - 6 (dead). A score of 0 is no disability, 5 is disability requiring constant care for all needs; 6 is death.
Time frame: Baseline
Time frame: Baseline, 14 and 28 days
Mid-upper arm circumference: measured at the midpoint between the acromion and the olecranon with the arm relaxed (2 measurements) in cm. Arm muscle circumference and area are calculated using the Heymsfield formula.
Time frame: Baseline, 14 and 28 days
Calf circumference: measured in the seated position, with the knee at a right angle, at the widest part of the non-paretic calf, with the tape snug but without compression (2 measurements) in cm. Calf circumference below 34 cm in men and 33 cm in women is classified as reduced.
Time frame: Baseline, 14 and 28 days.
Handgrip dynamometry: performed in the seated position with the elbow at a right angle; three trials on the non-paretic hand, with the mean value used for analysis. Handgrip strength of the non-paretic hand below 27 kg in men and 16 kg in women is classified as reduced.
Time frame: Baseline, 14, 28, and 90 days
Time frame: Baseline, 24 hours, 7 and 14 days.
Min - 0, max - 42. A higher score means a patients has more severe symptoms. Patients with a score of <4 are highly likely to have good clinical outcomes.
Time frame: Baseline, 14 and 28 days.
Min - 0, max - 15. Higher scores indicate better mobility performance. A score of 0 indicates an inability to complete any of the 15 tasks.
Time frame: 14 and 90 days
Mortality rate at 14 and 90 days
Time frame: Up to 28 days
Days. Total number of days spent admitted to the hospital during the index hospital stay, calculated from admission date to final discharge date.
Time frame: Up to 28 days
Days. Total number of days spent in the intensive care unit from the time of initial ICU admission to successful transfer or discharge to a step-down unit.
Time frame: From baseline to 90 days
University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)
Other
Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03569735
Atrophy, Body Weight
Shenzhen, Guangdong, China
View Trial DetailsNCT07708597
Atrophy, Brain Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT06910254
Atrophy, Brain Diseases
Seoul, South Korea
View Trial DetailsNCT07492849
Atrophy, Brain Diseases
Kaohsiung City, Taiwan
View Trial Details